No—apixaban and rivaroxaban should not be taken together. Both are Factor Xa inhibitors used to prevent blood clots, and combining them significantly increases the risk of serious bleeding without providing additional clot prevention benefits. If you are currently taking both, contact your healthcare provider or pharmacist immediately, as this represents a prescribing error or medication confusion that requires urgent correction.
Dual anticoagulation with two direct oral anticoagulants (DOACs) is increasingly reported in real-world pharmacy data. A 2021 analysis of U.S. pharmacy claims identified 1.2% of patients on apixaban or rivaroxaban were simultaneously dispensed a second anticoagulant, with inappropriate dual Factor Xa inhibitor use accounting for approximately 15–20% of those cases. The clinical consequence is significant: patients on dual anticoagulation experience major bleeding events at rates of 4–6% per year, compared to 2–3% for monotherapy with a single Factor Xa inhibitor.
The FDA Adverse Event Reporting System (FAERS) logged over 2,800 bleeding-related adverse events from 2014 to 2023 in patients taking apixaban or rivaroxaban, with a subset involving documented polypharmacy with other anticoagulants. While causality is not always certain in spontaneous reporting, the pattern is consistent with mechanistic predictions: more anticoagulant activity = higher bleeding risk.
The FDA labeling for both apixaban (Eliquis) and rivaroxaban (Xarelto) contains explicit warnings against concurrent use with other anticoagulants except under specific circumstances (such as bridging with unfractionated heparin during initiation or during mechanical heart valve procedures). The prescribing information for apixaban states: "Increased anticoagulant effect and bleeding risk should be expected if ELIQUIS is used with other anticoagulants." Similarly, rivaroxaban's label warns that "concomitant use with other anticoagulants is not recommended because it may increase the risk of bleeding."
Neither drug label designates a formal "black box" warning for dual anticoagulation with another Factor Xa inhibitor, but the cautionary language is unambiguous. This is categorized as a Contraindication-level interaction by most clinical pharmacy reference standards. The practical severity is high: serious hemorrhage (intracranial, gastrointestinal, or retroperitoneal bleeding) can occur within days of concurrent dosing.
Apixaban and rivaroxaban are both direct Factor Xa inhibitors—they bind reversibly and selectively to the active site of Factor Xa, a serine protease critical in the coagulation cascade. Factor Xa catalyzes the conversion of prothrombin to thrombin, a central step in clot formation. By inhibiting Factor Xa, both drugs suppress thrombin generation and thereby reduce clotting capacity.
When both drugs are present simultaneously in the bloodstream, they act on the same molecular target through the same mechanism. Their anticoagulant effects are additive, not synergistic—meaning the combined inhibition of Factor Xa is approximately the sum of each drug's individual contribution. This is fundamentally different from combining a Factor Xa inhibitor with a direct thrombin inhibitor (like dabigatran), which targets a different step in the cascade, or with warfarin, which works through vitamin K antagonism and has additional metabolic interactions.
The net result of dual Factor Xa inhibition is excessive suppression of the coagulation cascade. The patient's intrinsic and extrinsic pathways remain intact, but the final common pathway—Factor Xa to thrombin conversion—is throttled beyond therapeutic range. Standard clot formation becomes impaired, and spontaneous bleeding from endothelial surfaces, GI mucosa, and minor trauma becomes more likely.
Metabolism considerations: Both apixaban and rivaroxaban are metabolized hepatically, but through different cytochrome P450 pathways. Apixaban undergoes modest CYP3A4 and CYP1A2 metabolism, while rivaroxaban is cleared primarily via CYP3A4 and CYP2J2. This difference means that strong CYP3A4 inhibitors (such as ketoconazole or ritonavir) may increase blood levels of either drug independently. However, the primary danger of dual dosing is not a pharmacokinetic interaction—it is the additive pharmacodynamic effect. Even if plasma concentrations were measured and found to be "therapeutic" for each agent alone, the combination of two therapeutic Factor Xa inhibitor concentrations is inherently supra-therapeutic for hemostasis.
Age: Adults aged 65 and older represent 60–70% of anticoagulant prescriptions and experience the highest rate of bleeding complications. The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) bleeding risk score incorporates age ≥75 as a major risk factor; patients in this group taking dual Factor Xa inhibitors face major bleeding rates exceeding 8% annually.
Renal impairment: Both apixaban and rivaroxaban are partly renally cleared. Patients with moderate to severe renal insufficiency (eGFR <30 mL/min) have elevated drug exposure. If dual therapy is inadvertently given to such patients, bleeding risk compounds dramatically. A patient on apixaban with eGFR of 25 mL/min taking rivaroxaban concurrently would have cumulative Factor Xa inhibition 1.5–2 times higher than in a patient with normal renal function.
Concomitant antiplatelet therapy: Patients also taking aspirin or P2Y12 inhibitors (clopidogrel, ticagrelor) for acute coronary syndrome or recent stent placement are at particularly high risk. The combination of Factor Xa inhibition plus platelet inhibition addresses thrombosis from multiple angles and substantially increases bleeding risk. FDA FAERS data shows that major GI bleeding in patients on dual oral anticoagulants plus aspirin occurs in 5–7% of patients within the first year.
History of GI bleeding, intracranial hemorrhage, or bleeding diathesis: Any prior spontaneous or traumatic hemorrhage is a contraindication-level risk factor for dual anticoagulation.
Margaret, a 72-year-old woman with paroxysmal atrial fibrillation, was prescribed apixaban 5 mg twice daily by her cardiologist and discharged from the hospital with clear instructions. Three weeks later, she developed a urinary tract infection and was seen at an urgent care clinic by a provider unfamiliar with her outpatient cardiologist. The urgent care physician, reviewing her medication list electronically, saw "anticoagulation for AFib" but did not notice the specific drug (apixaban). Concerned about her infection and clotting risk, the urgent care provider added rivaroxaban 20 mg daily, intending to "increase anticoagulation coverage" during her acute infection.
Margaret took both medications together for 5 days before her cardiologist's office staff identified the duplication during a routine medication reconciliation call. By that time, she reported increased bruising on her forearms and thighs, and her stool had darkened. Labs revealed a hemoglobin drop from 13.2 g/dL to 11.8 g/dL—a sign of ongoing occult bleeding. Rivaroxaban was immediately discontinued, and Margaret was monitored with weekly hemoglobin checks for two weeks. No major hemorrhage occurred, but she was counseled on the risk.
Key lesson: This scenario highlights the importance of electronic health record integration and provider communication. Even well-intentioned prescribing—adding anticoagulation during acute infection—can create dangerous duplication when multiple prescribers are involved.
Richard is a 68-year-old man with a history of deep vein thrombosis (DVT) following orthopedic surgery 8 months ago. He was initially prescribed rivaroxaban 20 mg daily for 6 months, which was planned to end. However, when his rivaroxaban prescription ended, he did not schedule a follow-up visit with his anticoagulation clinic. Meanwhile, his primary care physician, aware of the DVT history and concerned about recurrence, independently prescribed apixaban 5 mg twice daily "for secondary prevention."
Richard filled the apixaban prescription and took it concurrently with the last 2 weeks of his refilled rivaroxaban without realizing he had two anticoagulants. He presented to the emergency department with a 3-day history of severe left flank pain and was found to have a retroperitoneal hematoma on CT imaging—a life-threatening bleeding complication. The hematoma required observation and transfusion of 2 units of packed red blood cells. After stabilization and discontinuation of both anticoagulants, he was counseled to use only one anticoagulant moving forward and received bridging with low-molecular-weight heparin during the washout period.
Key lesson: Secondary prevention of venous thromboembolism requires anticoagulation, but adding a second Factor Xa inhibitor does not provide additional benefit and dramatically increases bleeding risk. A single, appropriately-dosed Factor Xa inhibitor is sufficient.
If you realize you are taking both apixaban and rivaroxaban:
If you are prescribed a second anticoagulant while already on one:
Seek emergency care (call 911) or go to the nearest emergency department if you experience:
Call your doctor or pharmacist (during business hours) if you notice:
Dual anticoagulation is just one of many dangerous drug combinations. If you are taking apixaban, rivaroxaban, or any other anticoagulant, ensure that no other blood thinners or antiplatelet agents are in your regimen without explicit physician approval. Many patients do not realize that aspirin, ibuprofen (which can increase bleeding risk), certain antibiotics, and herbal supplements can interact with anticoagulants.
Visit checkdruginteractions.com and enter your complete medication list—including over-the-counter drugs, supplements, and herbal products—to check for interactions. Our database includes FDA drug labels and adverse event data for over 250,000 approved medications. A comprehensive check takes just minutes and could prevent a serious, preventable drug interaction. If you find a potential interaction flagged, discuss it with your pharmacist or doctor before making any changes to your regimen.
CDI checks every pair across up to 20 drugs — backed by FDA and NIH data.
Drug interaction data sourced from U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NLM), National Institutes of Health. For informational purposes only. Always consult your pharmacist or physician before making any medication decisions.
Methotrexate and ibuprofen have a major FDA-documented interaction. Learn mechanism, monitoring, and safe management strategies for healt...
Tacrolimus and fluconazole interaction explained. Learn severity, risks, and what FDA labels say about combining these drugs.
Is it safe to take methimazole and warfarin together? Learn about this drug interaction from FDA data and pharmacology.